TABLE 1

Characteristics of the Pediatric Asthma Population by Well-Child Adherence

CharacteristicWell-Child Attendance GroupsP
Children With Full Visit AttendanceChildren With Partial Visit AttendanceChildren With No Visit Attendance
Total, n (%)1855 (32.8)3033 (53.6)768 (13.6)
Male sex, n (%)1029 (55.5)1723 (56.8)438 (57.0).6125a
Race and/or ethnicity, n (%)<.0001a
 Hispanic186 (10.0)330 (10.9)168 (21.9)
 Non-Hispanic Black981 (52.9)1911 (63.0)429 (55.9)
 Non-Hispanic white480 (25.9)533 (17.6)124 (16.1)
 Other164 (8.8)204 (6.7)36 (4.7)
 Unavailable or unknown44 (2.4)55 (1.8)11 (1.4)
Age group, n (%)<.0001a
 5–111242 (67.0)2076 (68.4)461 (60.0)
 12–18613 (33.0)957 (31.6)307 (40.0)
Insurance status, n (%)<.0001a
 Public827 (44.6)1033 (34.1)196 (25.5)
 Private987 (53.3)1892 (62.4)515 (67.1)
 Self-pay39 (2.1)106 (3.5)57 (7.4)
Atopy at any time, n (%)1183 (63.8)2036 (67.1)358 (46.6)<.0001a
BMI for age percentile, median (IQR)75.2 (45.4–94.0)79.8 (51.4–95.6)86.6 (49.8–97.9)<.0001b
Obesity, n (%)426 (23.0)803 (26.5)259 (33.7)<.0001a
Medication category, n (%)<.0001a
 No ICS, LABA, LTRA, LAMA, or biological1469 (79.2)2544 (83.9)627 (81.6)
 Only ICS or only LTRA311 (16.8)391 (12.9)90 (11.7)
 All other categories75 (4.0)98 (3.2)51 (6.6)
No. encounters in the past y, median (IQR)3.0 (1.0–5.0)3.0 (1.0–5.0)3.0 (2.0–6.0)<.0001b
  • IQR, interquartile range; LABA, long-acting β-2 agonist; —, not applicable.

  • a χ2 test.

  • b Kruskal-Wallis test: For patients with at least 1 well-child visit, these represent the values on the date of the first well-child visit. For patients without at least 1 well-child visit, these represent the values on the date the patient became eligible for the asthma cohort.